After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble There's no denying that PharmaCyte Biotech (PMCB) stock has lost much of its value over the years. However, recent developments could catalyze a price...
By David Moadel •
This story originally appeared on StockNews
There's no denying that PharmaCyte Biotech (PMCB) stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence.
Cheap stocks can be fun and profitable to trade, as long as you're careful. Today I'd like to feature PharmaCyte Biotech < OTCMKTS:PMCB> as PMCB stock is a fast mover that should interest risk-tolerant investors.
Of course, low-priced stocks can fall just as quickly as they can rise. Therefore, I don't recommend taking a huge position in PharmaCyte shares.
That being said, a moderate stake in PMCB stock could yield sizable returns. Plus, you can feel good about investing in PharmaCyte Biotech as the company battles against life-threatening diseases.
Moreover, there's some good news for current and prospective investors in this tiny biotech firm. We'll get to that in a moment - but first, a quick overview of the share price's history.
A Closer Look at PMCB Stock
It's not every day that you'll hear about a company enacting a 1-for-1,500 stock split. Yet, this actually happened with PMCB stock.
In July, PharmaCyte Biotech announced that it would effect a 1-for-1,500 reverse share split of its common stock. These shares would commence trading on the OTCQB Exchange at the opening of the market on July 12, 2021.
With that, the number of outstanding common stock shares would decline from around 2.4 billion to approximately 1.6 million.
So, on a split-adjusted basis, PMCB stock traded at $8.26 on July 12. Unfortunately, the stock's value fell after that.
By early September, the recently adjusted PharmaCyte Biotech shares were trading at $3 and change.
At the same time, PharmaCyte Biotech had trailing 12-month earnings per share of -$2.45.
I'm presenting you with the bad news right up front, so you won't start loading up on PMCB stock without knowing all of the facts first.
Okay, so we got the hard part out of the way. Now, we can see if there's any positive news to report.
A Necessary Step
Some folks might wonder why PharmaCyte chose to enact a reverse share split in the first place. That's a valid question.
One possibility is that the company might have sought to pump up the share price, as stocks tend to appear more respectable above $1 than below it.
However, there's another reason for the reverse split, which was stated by PharmaCyte Biotech CEO Kenneth L. Waggoner:
"[W]e believe this change will make it easier for investors to trade in our stock and is a necessary step before the Company's common stock can be listed on a national stock exchange like Nasdaq, which is our expectation."
Call it a sneaky trick or a savvy move, but effecting a reverse split to get PharmaCyte shares listed on the Nasdaq Exchange is a plan so clever that it just might work.
An Important Milestone
It's a good thing that I regularly read InvestorPlace contributor William White's up-to-the-minute market reports.
Otherwise, I might have missed White's recent article on PharmaCyte Biotech.
In it, he provides an excellent summary, stating that PharmaCyte is a company that develops cellular therapies for cancer and diabetes.
For this purpose, PharmaCyte has a proprietary cellulose-based live-cell encapsulation technology, known as Cell-in-a-Box (one of my favorite product names ever).
That's important to know, but what really captured my attention was a huge piece of news.
Specifically, PharmaCyte Biotech's common shares escaped from the over-the-counter markets, and were upgraded to the Nasdaq Exchange.
Understandably, Waggoner called this event "an important milestone in PharmaCyte's life cycle."
The CEO added that getting uplisted to the Nasdaq Exchange will provide multiple benefits for PharmaCyte Biotech.
"We believe being a Nasdaq-listed company will help elevate our public profile, expand our shareholder base, improve liquidity and enhance shareholder value," Waggoner explained.
The Bottom Line
Did the reverse share split of PMCB stock directly lead to the Nasdaq Exchange uplisting?
It's hard to know for sure. Nonetheless, the upgrade is definitely a positive development.
Perhaps it will provide PharmaCyte Biotech with enhanced investor interest, along with an influx of capital to help the company pursue its clinical work.
Isn't it amazing how unorthodox plans can work out for the best sometimes?
The stock market can be unpredictable, volatile, and sometimes totally nonsensical. InvestorPlace.com strives to cut through the noise and bring you information on what matters – and how it impacts your portfolio. We deliver thoughtful coverage on everything from stocks to cryptos to pre-IPO investments. So whether you live and breathe breaking stock news or expect your stocks to pay you, InvestorPlace.com has your back.
On the date of publication, David Moadel did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
PMCB shares fell $3.40 (-100.00%) in premarket trading Tuesday. Year-to-date, PMCB has declined %, versus a 21.96% rise in the benchmark S&P 500 index during the same period.
About the Author: David Moadel
David Moadel has provided compelling content – and crossed the occasional line – on behalf of Crush the Street, Market Realist, TalkMarkets, Finom Group, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.
The post After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble appeared first on StockNews.com
